OBJECTIVES: Transapical (TA) aortic valve implantation using the Edwards SAPIEN™ bioprosthesis was commercially introduced in Europe in January 2008. Limited data on the mid-term results are available.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has been pioneered using the transfemoral (TF) and transapical (TA) approaches [1] [2] [3] . In contrast to TF TAVI, access through the left ventricular apex is not restricted in size and there are almost no patients in whom TA TAVI is technically not feasible [4] . This may explain why, despite the development of alternative access routes through the subclavian artery and the ascending aorta, the vast majority of non-TF TAVIs is performed using TA access [5] [6] [7] .
The Edwards SAPIEN™ transcatheter heart valve (Edwards Lifesciences, Irvine, CA, USA) was the first balloon-expandable valve suitable for TF and TA access. CE-Mark certification for TA TAVI was received in January 2008 and, until recently, it was the only device available for this access route. Prospective randomized data of TA TAVI versus surgical aortic valve replacement (sAVR) have been published by the PARTNER-US investigators [8] . It shows that the 1-year survival in patients seen to be at high risk for sAVR, who do not have suitable peripheral access to TF TAVI, is not significantly different between the two groups.
Unfortunately, and in contrast to TF TAVI, prospective randomized data between TA TAVI and medical treatment for patients who are seen to be inoperable using sAVR have not been generated during the PARTNER-US trial [9] .
Single-centre experience with TA TAVI has been presented recently and excellent mid-term results have been reported [10, 11] . European multicentre, real world data have been collected since November 2007 using the SOURCE Registry and 30-day and 1-year results published previously [12] [13] [14] . However, given that TA TAVIs in Europe are nowadays performed using the second-generation TA device (Edwards SAPIEN XT™, Edwards Lifesciences, Irvine, CA, USA), and given that new devices of other manufacturers have recently been approved for TA TAVI in Europe, it is important to have mid-/long-term outcome from the SOURCE Registry as a baseline for future comparison.
PATIENTS AND METHODS

Registry
The SOURCE Registry is currently the largest and most comprehensive data set on the experience with the Edwards SAPIEN™ transcatheter heart valve in Europe, totalling 2307 patients (TA 60.1%, TF 39.8%). The Registry's methodology, as well as inclusion criteria for patients and centres, procedures and devices, training and proctoring for the procedures, definitions and data collection have been described previously [15] . In all patients of this study, the Ascendra™ introducer sheath (Edwards Lifesciences, Irvine, CA, USA) was used to implant a 23 mm or 26 mm Edwards SAPIEN™ valve.
In order to produce a scientifically robust data set, only centres that could provide data on 100% of their consecutively treated patients between November 2007 and December 2009 were included in the present analysis.
A total of 1387 patients in the SOURCE Registry underwent TA TAVI in 38 centres as reported previously (see online supplementary material Table S1 for a list of participating centres). Two centres elected not to participate in the Registry, and one centre was excluded due to data non-compliance.
Purpose of this study
In this manuscript, we present the interim 2-year analysis for patients who underwent TA TAVI on an intention-to-treat basis. We analyse the risk factors for mid-term mortality, and identify the causes of death in these patients. In addition, univariable and multivariable analyses are presented to identify the predictors for 2-year mortality after TA TAVI.
Definitions and data collection
Definitions and the methodology of data collection in the SOURCE Registry were reported previously [12] .
For the total group of TA patients (n = 1387), the completeness of 30-day data, 1-year data and 2-year data for patients with the follow-up performed is now 100, 99.8 and 98.9%, respectively, at the time of the data extraction. The mean follow-up is 14.9 months, with 1004 patients who completed 1 year and 464 patients who completed 2-year follow-up.
Events and values collected are site reported and there are no core laboratories. The principal investigators (O.W., M.T.) reviewed and adjudicated all clinical and adverse events reported into the Medidata RAVE electronic database (Medidata Solutions, Inc., USA).
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are given as frequencies and percentages. All statistical analyses were performed using SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA).
Two-year survival is based on days past the valve implant, without consideration of discharge from the hospital. The proportion of patients censored prior to 2 years is 30.5%, and pure proportion and Kaplan-Meier estimates of 2-year survival differ by 3.8%. For ease of presentation and computation, 2-year survivals were evaluated as pure proportions except where otherwise stated in the manuscript text.
Missing baseline data are a potential issue in risk analyses. The STS (Society of Thoracic Surgeons) risk score was missing in 38.5% of patients, and therefore this variable was not used in the risk analyses. Use of the word EuroSCORE in this manuscript refers to the mean logistic EuroSCORE. Univariable and multivariable risk analyses were performed by Cox regression analyses, comparing risk factors with the 2-year survival. No imputation was made for missing data in the univariable analyses. Missing baseline values were imputed to be the mean of observed values in the multivariable analyses. Wald P-values are presented for Cox regression analyses.
Statement of responsibility
The principal investigators had full access to the reported data and take responsibility for the integrity of the data presented in the manuscript. All authors have read and agreed to the manuscript as written.
RESULTS
Baseline characteristics
The patients had a mean age of 80.6 ± 7.1 years and predominantly female gender (59%). The risk profile was high for all TA patients and resulted in a mean logistic EuroSCORE of 27.6 ± 16.1. The most important general comorbidities noted were renal insufficiency (31.2%), diabetes mellitus (28.6%), peripheral vascular disease (26.4%), respiratory disease (26.1%), carotid artery stenosis (15.1%), porcelain aorta (10.2%) and previous stroke (6.5%) ( Table 1) .
Cardiac comorbidities were dominated by coronary artery disease (55.8%), with previous coronary intervention in 28.5% and previous coronary artery bypass grafting in 25.5% of patients. Congestive heart failure was reported in 28.4%, although severe left ventricular dysfunction (ejection fraction <30%) was only noted in 5.6% of patients. The total number of patients with concomitant mitral valve disease was relatively high (36.3%) and a small number of patients had undergone previous sAVR (1.7%) ( Table 1) .
Procedural data
In the majority of patients (60.6%), a 26 mm Edwards SAPIEN™ valve was inserted. The incidence of valve malposition (1.4%), valve embolization (0.7%) and aortic regurgitation of >2+ (5.9%) was low. This helps explain why the number of valve-in-valve procedures in which an Edwards SAPIEN™ was deployed inside an Edwards SAPIEN™ was small (2.2%). The cardio-pulmonary bypass was used in only 1.2% of patients and conversion to open-heart surgery needed in 0.7%. This resulted in a procedural success (defined as one Edwards SAPIEN™ valve inserted, aortic regurgitation not >2+ and patient leaves operating room alive) of 92.4% (Table 2) .
Adverse events
The 30-day mortality was 11.3% with the main adverse events noted to be permanent pacemaker implantation (7.1%), renal failure requiring dialysis (6.7%), major bleeding events (3.9%), vascular/access-related complications (2.6%) and stroke (2.5%) ( Table 3) .
During the 2-year follow-up, freedom from valve related adverse events such as endocarditis (99.1%) and valve thrombosis (99.9%) was high. Freedom from new pacemaker implantations was 91.1% and late myocardial infarcts were rare (freedom from 98.4%). Freedom from stroke was 95.2% at 1-year and 93.9% at 2-year follow-up. Renal failure requiring dialysis did not play a major role during the follow-up and was observed in only 0.1% of patients beyond 30 days. Overall Kaplan-Meier survivals at 1 year and 2 years were 73.8 and 65.1%, respectively (Fig. 1) .
Causes of the 276 deaths observed between >30 days and 2-year follow-up were cardiac in 86 patients (31.2%), non-cardiac in 142 (51.4%) and unknown in 48 (17.4%). Cardiac causes of death included heart failure (n = 29, 33.7%), sudden cardiac death (n = 29, 33.7%), myocardial infarct (n = 7, 8.1%), endocarditis (n = 5, 5.8%) and others (n = 16, 18.6%). Non-cardiac deaths were related to pulmonary disease (n = 30, 21.1%), cancer (n = 18, 12.7%), renal failure (n = 16, 11.3%), stroke (n = 15, 10.6%), gastrointestinal disease (n = 11, 7.7%) and others (n = 73, 51.4%) (Fig. 2) .
Causes of death during the first year after the procedure were mainly of non-cardiac nature (52.7%) and dominated by pulmonary disease (23.4%), stroke (12.1%), cancer (9.3%), renal failure (8.4%) and gastrointestinal complications (6.5%). Cardiac causes were observed in 31.5% of patients and were dominated by heart failure (34.4%) and sudden cardiac death (32.8%) (Fig. 2a) . During the second year period, the percentage of non-cardiac deaths remained the highest, with a similar ratio between non-cardiac and cardiac deaths (47.9 versus 30.1%). Most common non-cardiac causes during the second year follow-up were cancer (22.9%), renal failure (20.0%) and pulmonary disease (14.3%). Sudden death was the most frequently observed cardiac cause of death with 36.4%, followed by heart failure (31.8%) and myocardial infarction (13.6%) (Fig. 2b ).
Univariable and multivariable analysis
A univariable analysis including all baseline characteristics was performed to identify the predictors of 2-year mortality (Table 4) . Strongest predictors were a scaled logistic EuroSCORE and renal insufficiency, followed by peripheral vascular disease, liver disease, arrhythmia, congestive heart failure and pulmonary disease. Lower 2-year mortality was observed in females and patients with hyperlipidaemia/hypercholesterolaemia (Table 5) . Multivariable analysis identified scaled logistic EuroSCORE, renal insufficiency and liver disease as independent predictors of 2-year mortality. Female gender and hyperlipidaemia/hypercholesterolaemia were independent predictors of improved outcomes (Table 5) .
DISCUSSION
TAVI is a rapidly developing treatment for which the FDA approval has been given recently in patients unsuitable for sAVR. For patients facing high-risk sAVR, the results of the prospectively randomized arm of the PARTNER-US trial (Cohort A) show that all treatment modalities used, TF TAVI, TA TAVI but also sAVR, are acceptable treatment options in these patients. Although the 30-day mortality in the TAVI patients was the lowest ever reported for transcatheter heart valve treatment (TF 3.3%, TA 3.8%), 1-year mortality was still 22.2% (TF) and 29% (TA) [8] and (5), and other (2) . Pulmonary**= pneumonia (11) , respiratory failure (9) and pulmonary embolism (5) . Other*** = multiple organ failure (14) , sepsis (13) , infection (6), haemorrhage (1), aneurysm (1), suicide (1) and other (7) . (b) Causes of death between 1 year and 2 years. Other* = arrhythmia (1), cardiac arrest (1) and other (1) . Other** = multiple organ failure (1), sepsis (2), major bleeding (1) and other (5). thus not much different from the 1-year mortality reported previously from the European SOURCE Registry (TF 19.9%, TA 25.8%), also using the Edwards SAPIEN™ valve [12] . This may be even more interesting, as SOURCE is an all comers registry, including high-risk but also inoperable patients, in contrast to Cohort A, which is a selected high-risk group of patients with an estimated sAVR mortality of ≥15%, but <50% [8] .
In Europe, TAVI is mainly performed through TF or TA access; however, early experience using access through subclavian artery and ascending aorta has been reported [5] [6] [7] . Since CE-Mark certification for the Edwards SAPIEN™ has been received in 2007, perioperative results have constantly improved due to the reduction in intraoperative technical failures, and the results of the learning curve have been reported [15, 16] . Single centres have achieved outstanding outcomes with 1-year/2-year survival of 73%/68% [10] and 83%/65%, respectively [11] . These recent data from 38 centres included in the SOURCE Registry show a comparable 1-year survival of 73.8% with a survival at 2 years of 65.1%. Multivariable analysis revealed that particularly in patients with a very high EuroSCORE, concomitant renal or liver disease have a high prognostic risk for 2-year mortality. In addition to these excellent survival rates, structural valve failure has not been reported and endocarditis or other valve related complications are low.
For the discussion of yearly mortality in this elderly group of patients, it is important to keep in mind what the expected survival for a peer group of the same age is. In the European Union, a 75-year old citizen can expect to survive around 11 additional years [15] and, in the USA, octogenarians are currently expected to live for a further 8.5 years [16] . In terms of mortality per year, this calculates to 9.1% in Europe and 11.8% in the USA. In fact, a yearly death rate of 8% after the initial perioperative period of TA TAVI is therefore close to, or even better than, what is naturally expected of a reference group of this age.
Causes of death identified are mainly non-cardiac related. Although respiratory complications and strokes were more often 
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identified as the cause of death during the first year after transcatheter heart valve treatment, cancer and renal complications, not surprisingly, play an increasing role during the longer followup. Heart failure as expected is the most common cardiac cause of death. In this context, it is worth mentioning that sudden cardiac deaths account for around one-third of all cardiac deaths. This, of course, reflects the significant number of cases for which only limited information on the cause of death is available, and therefore a differentiated analysis is difficult to make. It is also worth mentioning that although this is a multicentre registry, including early experience with TA TAVI, the incidence of major vascular/access complications is low (at ≤30 days 1.5%). This finding is also supported by the low incidence of conversion to conventional surgery (0.7%) and cardio-pulmonary bypasses used (1.2%) during the procedure. With respect to the recurring discussion regarding the surgical safety of the TA access, this clearly demonstrates that access through the left ventricular apex is safe in experienced hands.
Stroke has been raised as a cause of concern in the PARTNER-US trial and was actually reported to be higher after TAVI compared with sAVR [8] . Although the incidence of stroke ≤30 days in the SOURCE Registry is low (2.5%), it is worth mentioning that there is a constant incidence of stroke per year, which leads to a freedom of stroke at the 2-year follow-up of only 93.9%. This is most likely a result of the elderly cohort of patients with a mean age of >80 years.
However, with respect to stroke, it is worth mentioning that the TA approach is the only transcatheter access option, where the passage of the native aortic valve is achieved through an antegrade direction. This makes it technically easier to pass the aortic valve and potentially reduces the risk of plaque dislocation. Although previous reports of the SOURCE Registry have not shown a significant difference in the incidence of perioperative stroke between TA (2.6%) and TF (2.4%) access, one needs to keep in mind that the TA cohort of patients had a significantly higher risk profile of suffering from a perioperative stroke compared with TF [17] .
This still raises the question in which way the access itself, generally TF or TA, has a bearing on the outcome. Interestingly, data from the PARTNER-US trial shows that the lack of peripheral vascular access could be a negative predictor of 1-year mortality in general. Although, at present, there is no detailed statistical analysis provided on these two groups of patients, it is striking that patients without adequate peripheral vascular access, who therefore were randomized between TA TAVI and sAVR and who underwent sAVR, faced a higher 1-year mortality (27.9%), compared with their peers with suitable vascular access, who were randomized to undergo sAVR (26.4%) [8] . As TA access is feasible in almost all patients, it is most often used in patients with restricted vascular access due to the size or quality of the peripheral arteries. This explains the higher incidence of peripheral vascular disease and other cardiovascular risk factors found in TA cohorts not only in SOURCE [12] , but also other registries [18] . The Canadian TAVI Registry is also interesting in this respect, as it shows that although the TA group of patients presented with more comorbidities, perioperative and mid-term outcomes were similar compared with TF patients, with 30-day mortalities of 9.5 (TF) and 11.3% (TA), 1-year survival of 75 (TF) and 78% (TA) and 2-year survival of 65 (TF) and 64% (TA), respectively. Most strikingly, the mode of access, TF or TA, had no prognostic value in terms of survival [18] .
Currently, there are no randomized trials between TF TAVI and TA TAVI available. Data from a relatively small Swedish propensity matched cohort suggest that there is no difference in survival found between patients treated using TF and TA access route [19] . However, we hope to present a propensity-matched analysis of the two cohorts from the SOURCE Registry in the near future. For these comparisons, it is important to keep in mind that an appropriate comparison of the two approaches should not only focus on mortality, but should also include postoperative recovery time, post-implantation aortic regurgitation and complications such as the need for the implantation of a permanent pacemaker.
For the discussion on the value of TF versus TA access routes, it is also important to keep in mind that currently TA TAVI is the preferred option for the treatment of failing bioprostheses using the Edwards SAPIEN™ transcatheter heart valve, and excellent results have been reported [20] . This is also reflected in the SOURCE Registry, where the number of patients who receive treatment for failing aortic bioprostheses is continuously increasing, to currently 1.7%.
The presented 2-year follow-up data are also important as it can be used as a standard of practice for future comparison. Since 2010, the second generation of the SAPIEN™ balloonexpandable transcatheter heart valve, the Edwards SAPIEN XT™ valve has been implanted and outstanding 30-day and 1-year results have been reported recently [21] . After the new valve received CE-Mark certification, patients treated have been included in the SOURCE XT Registry and it is anticipated that early results will be presented this year. One would hope that due to the reduced size of the deployment device, improved heart valve features and the very low early mortality in Prevail-TA (30-day mortality: 8.7% for 23 mm and 26 mm valves, 4.5% for 29 mm), real world outcome from the SOURCE XT Registry will also improve. In addition, data from the SOURCE registry can be used as a reference for TA devices of other manufacturers, which recently received the CE-Mark certification in Europe such as JenaValve™ ( JenaValve Technology GmbH, Munich, Germany) and Acurate TA™ (Symetis Ecublens, Switzerland). The presented data show that TA TAVI is an excellent treatment option for patients at high risk for sAVR. Interestingly, all the mentioned studies that reported on the mid-term follow-up results including SOURCE result in a survival of 65% at 2-year post-surgery. It will be interesting to see how new devices and technical modifications will improve these outcomes in the future. For this to happen, the heart team will continue to be of importance in the future, as it provides a unique mixture of skills that will guarantee that patients receive the most appropriate type of jointly agreed treatment under optimal circumstances.
Limitations of the SOURCE Registry
The SOURCE Registry is a clinical registry and contains a limited functional assessment of the Edwards SAPIEN™ valve. In addition, all adverse events were self-reported by the participating centres; no adjudication of adverse events via source documentation was assessed.
However, review and adjudication of all serious adverse events and adverse events in the electronic database were performed by the principal investigators. Dr Wendler: Well, for the Registry I cannot really answer that question, because, as you say, it is a self-reported registry. Decisions about patient treatment are made by the centres and the investigators themselves, and there is no inclusion or exclusion criteria built into this Registry.
APPENDIX. CONFERENCE DISCUSSION
The one thing which is important to recognize about this Registry is that all of these patients are a consecutive group of patients. So compared to data
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O. Wendler et al. / European Journal of Cardio-Thoracic Surgeryfrom other registries, there is less bias due to selection of patients. Completion of data is completely different than you see in a lot of other registries because it is 99% complete in terms of data. So the reason why I cannot answer this question about the preoperative bypass is that it is not part of our questionnaires, but with regard to the data, I think it is quite robust data. But it is self-reporting; you are absolutely right.
Dr Schlensak: Second question. As you mentioned before, in your previous talk, you demonstrated an increase in aortic regurgitation over time, i.e. one month or later after valve implantation, although there was no reported regurgitation from the implantation. What is the mechanism for that? Do you have any idea about the reason for the increase in regurgitation?
Dr Wendler: That is, again, one of the weaknesses of this type of registry; there is no core lab-adjudicated echo data available. And that's the reason why, if I were asked what is maybe the weakest data in this Registry, then it is, I believe, the self-reported echocardiography data. The reason is that from trials such as the PREVAIL trial or the 29 mm Sapien investigation, we know that core lab-adjudicated echo data is often a little bit different than what self-reporting data reflects. So that's the reason why I would have problems in answering that question properly.
Dr Schlensak: It seems important to demonstrate the results of this Registry in order to have enough data in the hands of us surgeons to be able to discuss the potential benefit of transapical valve implantation in comparison to the transfemoral or transaxillary access.
Dr V. Falk (Zurich, Switzerland): Olaf, one more question. It is a pity that we don't have core lab results for the echo, but this can't be changed. With this large cohort you should be able to analyse whether paravalvular leakage is an independent risk factor for late mortality, as has been indicated in more recent publications. Did you factor this into your univariate analysis?
Dr Wendler: It would have been elegant if we had done this. On the other hand, the reason why have not done this analysis is that, as I said, the echo data, from my point of view, is too weak to really go that route. On the other hand, we have planned some changes for the next generation of the SOURCE registry, the XT registry which is based on experience using the Edwards Sapien XT valve. We will try, at least in a subgroup of centres, to go the route of having echo data core lab adjudicated, because we realize that that's one of the weaknesses at present. Another weakness is, of course, that, for example, we don't have good data on frailty or on exercise capacity, and that's something else which we will address.
However, we should not forget that all the centres contributing to the SOURCE registry do a brilliant job. It is a lot of work that they have to invest in this Registry. Nevertheless, it is often difficult to get all the data, not because performance is low in the centres, but just because it is such a big group of patients. But you're right, there is room for improvement. We try to get changes implemented into the SOURCE XT registry so that we have more information on these kinds of questions in the future.
Dr D. Wendt (Essen, Germany): Just one short comment. How was liver disease defined? You showed that liver disease results in a two-fold increase in mortality. So what is the definition of liver disease?
Dr Wendler: It is not specified particularly. I think there are a number of fields which should be more specified in the future, and that will happen in the SOURCE XT registry.
Dr G. D'Ancona (Berlin, Germany): I have a question concerning coronary artery disease. There is a high rate of patients with coronary artery disease, concomitant coronary artery disease, either treated or, as you posed, also untreated. At the Deutsches Herzzentrum Berlin, we have developed a very specific strategy for those patients and in many cases we do concomitant PCI. I was wondering, as this is a multicentre trial, could you speculate a little bit about the trend in the trial, how the participants behave when there is concomitant coronary artery disease, what the rate of concomitant PCI would be, would it be performed before TAVI, would it be done at a later stage, would it be a complete revascularization, or a target revascularization? Because I think this is a very important issue.
Dr Wendler: I completely agree that it is an important issue. I think the problem we have is that we know very well about the incidence of coronary artery disease. We don't know very well about the incidence of myocardial ischaemia in these patients. Patients may have had bypass surgery in the past and maybe nicely revascularized, or they may have a problem that all the button grafts are gone. We don't have a good idea about the ischaemia burden in this cohort of patients. Nevertheless, this would be information we would need to answer your question, as we would be able to say 'okay, out of the number of patients who had coronary artery disease and had presented with ischaemia, a number of them have been treated with PCI at the time of the TAVI, or before TAVI as a staged procedure, or have not been treated'.
I think there is a lot of debate about whether that's needed or not, and there are a number of colleagues, particularly cardiologists, who believe that we do not need to treat coronary artery disease before TAVI. On the other hand, looking at the two-year results and looking at the fact that myocardial infarct as a cause of death in these patients is increasing now, something which I had expected, I believe that one needs to address coronary artery disease maybe more in the future. Dr Falk: That was a clear answer.
